The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
Open accessAbstract
Purpose: Population studies have suggested that metformin use in diabetic patients decreases cancer incidence and mortality. Metformin inhibits the growth of cancer cells in vitro and tumors in vivo. However, there is little clinical data to support this. Our purpose was to determine whether metformin use was associated with a change in pathologic complete response (pCR) rates in diabetic patients with breast cancer receiving neoadjuvant chemotherapy. Patients and Methods: We identified 2,529 patients who received neoadjuvant chemotherapy for early-stage breast cancer between 1990 and 2007. Patients were compared by groups: 68 diabetic patients taking metformin, 87 diabetic patients not taking metformin, and 2,374 nondiabetic patients. pCR rates were compared between the three groups using χ 2 tests of independence and compared pair- wise using a binomial test of proportions. Factors predictive of pCR were assessed using a multivariate logistic regression model. Results: The rate of pCR was 24% in the metformin group, 8.0% in the nonmetformin group, and 16% in the nondiabetic group (P = .02). Pairwise comparisons between the metformin and nonmetformin groups (P = .007) and the nonmetformin and nondiabetic groups (P = .04) were significant. Comparison of the pCR rates between the metformin and nondiabetic groups trended toward but did not meet significance (P = .10). Metformin use was independently predictive of pCR (odds ratio, 2.95; P = .04) after adjustment for diabetes, body mass index, age, stage, grade, receptor status, and neoadjuvant taxane use. Conclusion: Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pCR rate than do diabetics not receiving metformin. Additional studies to evaluate the potential of metformin as an antitumor agent are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin has also been found to cooperate with neo-adjuvant chemotherapy to result in complete tumor regression in some breast cancer patients (Jiralerspong et al., 2009).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Jiralerspong et al., 2009
In the citing paper
“Type 2 diabetic patients receiving neo-adjuvant chemotherapy for breast cancer as well as metformin were more likely to have pathologic complete response (pCR) than patients not receiving it.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [156]
In the citing paper
“However, despite the increase in pCR, metformin did not significantly improve the estimated 3-year relapse-free survival rate [156].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [156]
In the citing paper
“evidence that metformin may also have an adjunctive effect in patients receiving chemotherapy(270)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [270]
In the citing paper
“There is further evidence that metformin may also have an adjunctive effect in patients receiving chemotherapy(270), and there are now more than 100 ongoing trials”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [270]
In the citing paper
“Metformin treatment was associated with higher pathologic complete response among early-stage breast cancer patients receiving neoadjuvant therapy (95).”
From Diabetes and Cancer (2010) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
Insulin-like growth factors and neoplasia
Pollak, M., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1387 · Cited by 1,477
Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes
Muoio, D. M., & Newgard, C. B. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2327 · Cited by 1,177
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N. M., Manning, B. D., Lopez, L. V., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,107
Research works printed but not linked: 3
- Mieog JS, 2007, Cochrane Database Syst Rev, 2, CD005002
- 10.1200/JCO.2002.20.1.42 · DOI
- Fairey AS, 2003, Cancer Epidemiol Biomarkers Prev, 12, 721
Cited by
Sorted by citations
Items 601–700 of 879
Tumour, whole‐blood, plasma and tissue concentrations of metformin in lung cancer patients
Phillips, J. D., Pooler, D. B., Ness, D. B., Fay, K. A., Tau, S. S., Demidenko, E., Hampsch, R. A., Lewis, L. D., & Miller, T. W. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15546 · Cited by 13
Prevalence of diabetes in patients admitted to a cancer hospital
Morganstein, D. L., Tan, S., Gore, M. E., & Feher, M. (2012) · The British Journal of Diabetes · doi:10.1177/1474651412459091 · Cited by 11
The Intellectual Structure of Human Computer Interaction Research.
Shiau, W., Yan, C.-M., & Kuo, C.-C. (2016) · Journal of information science and engineering · Cited by 11
Serageldin, M. A., El‐Bassiouny, N. A., Elkerm, Y., Aly, R. G. M., Helmy, M. W., El‐Mas, M. M., & Kassem, A. B. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16193 · Cited by 10
“52 Whereas metformin was found efficacious in achieving high pCR rates when combined with neoadjuvant chemotherapy in diabetic BC patients, 48 – 50 no such effect was noted in nondiabetic BC patients.”
Panahandeh, P., Bertelsen, B.-E., Viste, K., Chatziioannou, A. C., Bellerba, F., Robinot, N. R., Trolat, A., Flågeng, M. H., Scalbert, A., Keski‐Rahkonen, P., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-01705-9 · Cited by 10
“In breast cancer patients with T2D, use of metformin during neo-adjuvant chemotherapy has inhibitory effects on tumor progression 37 .”
Morgans, A. K., Chen, Y., Jarrard, D. F., Carducci, M. A., Liu, G., Eisenberger, M., Plimack, E. R., Bryce, A. H., Garcia, J. A., Dreicer, R., et al. (2022) · The Prostate · doi:10.1002/pros.24369 · Cited by 10
“and metformin use has been found to improve outcomes in other hormonally‐mediated advanced cancers including breast and endometrial.(20,22) These results may be due in part to the adverse metabolic health effects of hormone ablation, which may be mitigated in diabetic men treated with metformin after ADT.”
BackgroundMitocans: Mitochondrially Targeted Anti-cancer Drugs
Boukalová, Š., Rohlenová, K., Rohlena, J., & Neužil, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-73344-9_27 · Cited by 12
Wahdan-Alaswad, R. S. (2018) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2018.09.555765 · Cited by 10
Metformin Indications, Dosage, Adverse Reactions, and Contraindications
Stoica, R. A., Ștefan, D. S., Rizzo, M., Suceveanu, A., Suceveanu, A. P., Serafinceanu, C., & Stoian, A. P. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.88675 · Cited by 11
Metformin alleviates endometrial hyperplasia through the UCA1/miR‑144/TGF‑β1/AKT signaling pathway
Guo, M., Zhou, J., & Huang, W. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4438 · Cited by 10
Guo, J., Liu, J., Qie, H., Zhao, F., & Niu, C. H. (2021) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2020.1870258 · Cited by 10
“Recently, MET sparked strong interest of using it as a potential anticancer agent for prostate cancer treatment [17, 18].”
BackgroundLifestyle and Breast Cancer Risk: The Way Forward?
Chlebowski, R. T. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7898 · Cited by 10
Ahmed, J., Stephen, B., Khawaja, M. R., Yang, Y., Salih, I., Barrientos-Toro, E., Raso, M. G., Karp, D. D., Piha-Paul, S. A., Sood, A. K., et al. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.12.019 · Cited by 9
Self-citationWilkie, M. D., Anaam, E. A., Lau, A., Rubbi, C. P., Vlatković, N., Jones, T. M., & Boyd, M. T. (2021) · Cancers · doi:10.3390/cancers13194836 · Cited by 9
“re-purposing metformin as a therapeutic agent in the context of cancer treatment [51], an interest which stems from several epidemiological studies demonstrating a lower cancer incidence in diabetic patients taking metformin than in the general diabetic population [52], and retrospective data indicating that metformin…”
BackgroundBarakat, H. E., Hussein, R. R. S., Elberry, A. A., Zaki, M. A., & Ramadan, M. E. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2051482 · Cited by 10
“The interpretation of this result according to the Jiralerspong study was based on two axioms.”
BackgroundInfluentialGadéa, É., Thivat, É., Wang-Lopez, Q., Viala, M., Paulon, R., Planchat, E., Chadeyras, J. B., Merlin, C., Coudert, B. P., Bignon, Y., et al. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1802 · Cited by 9
Marguerite, V., Gkikopoulou, E., Alberto, J., Guéant, J., & Merten, M. D. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.09.018 · Cited by 9
Diabetes medications and cancer risk: review of the literature.
Nguyen, Q. P. H., Sanders, L., Michael, A. P., Anderson, S. R., Nguyen, L. D., & Johnson, Z. A. (2012) · PubMed Central · Cited by 9
Patnaik, A., Locasale, J. W., & Cantley, L. C. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0598-6_13 · Cited by 9
Esophageal Cancer - Cell and Molecular Biology, Biomarkers, Nutrition and Treatment
Jazii, F. R. (2012) · InTech eBooks · doi:10.5772/1196 · Cited by 9
Resistance to neoadjuvant chemotherapy in breast cancers: a metabolic perspective
Desgres, M., Poyraz, M., Sari, B., Duhoux, F. P., van Marcke, C., & Corbet, C. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03500-w · Cited by 8
“Despite early promise, trials investigating metformin in NAC settings have produced inconclusive results [199, 200].”
Lord, S., Patel, N. S., Liu, D., Fenwick, J., Gleeson, F. V., Buffa, F. M., & Harris, A. L. (2015) · JNCI Monographs · doi:10.1093/jncimonographs/lgv011 · Cited by 7
“007) when compared with patients on other diabetes drugs (10).”
ResultTaromaru, G. C. M., de Oliveira, V. M., Silva, M. A. L. G., Montor, W. R., BAGNOLI, F., Rinaldi, J. F., & Aoki, T. (2011) · Oncology Letters · doi:10.3892/ol.2011.532 · Cited by 8
Dorris, J. R., & Jones, S. F. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014542415 · Cited by 8
“Complications of diabetes and obesity such as hyperinsulinemia, insulin resistance, and hyperglycemia have been associated with poor breast cancer outcomes.(35) Glucose and insulin are involved upstream in the PI3K/Akt/mTOR pathway; this further underscores the need for increased attention to glycemic control.”
BackgroundOgunsakin, A. A., Infield, J., Zuber, J., & Solomon, S. S. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.09.002 · Cited by 8
Maucort, C., Giorgio, A. D., Azoulay, S., & Duca, M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000251 · Cited by 9
Early treatment with metformin induces resistance against tumor growth in adult rats
Trombini, A. B., Franco, C. C. S., Miranda, R. A., de Oliveira, J. C., Barella, L. F., Prates, K. V., de Souza, A. A., Pavanello, A., Malta, A., Almeida, D. L., et al. (2015) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.962968 · Cited by 8
“The pathologic complete response rate to neoadjuvant chemotherapy in diabetic patients with breast cancer was higher in patients taking metformin than in patients who had not been treated.(4,11,12) Various strategies have been reported to prevent cancer and metabolic syndrome, such as exercise training, functional foo…”
BackgroundFloch, J. P. L. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s7315 · Cited by 10
“20 Reassuringly, in this context, metformin is emerging as a therapy with potential benefits, 21–23 but we may need to be mindful of potential differences between insulins.”
Scotlandi, K., & Belfiore, A. (2012) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2012.32.134 · Cited by 8
Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative
Prabhakaran, S., Thirumal, D., Gimbun, J., Ranganathan, B., & Palms Connect Sdn Bhd, S. A. 4. (2017) · Journal of Natural Remedies · doi:10.18311/jnr/2017/17938 · Cited by 8
Quimby, A. E., Lebo, N. L., Griffiths, R., Hall, S. F., Dimitroulakos, J., & Johnson‐Obaseki, S. (2018) · Journal of Otolaryngology - Head and Neck Surgery · doi:10.1186/s40463-018-0322-7 · Cited by 8
Godara, A., Siddiqui, N. S., Hachem, H., Tsichlis, P. N., Martell, R. E., & Saif, M. W. (2020) · Journal of Cellular Signaling · doi:10.33696/signaling.1.008 · Cited by 8
“Observational studies have demonstrated that metformin, an anti-diabetic drug is associated with reduced cancer incidence and mortality in multiple cancer types [1-4].”
BackgroundResultWorld Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease
Bloomgarden, Z. T. (2011) · Diabetes Care · doi:10.2337/dc11-0840 · Cited by 8
“Metformin has benefit across different subtypes of breast cancers (60) but may be most effective in “triple negative” breast cancer (61), with potential to abrogate resistance to human epidermal growth factor receptor-2– targeted therapies (62) and to increase aromatase inhibitor effects (63).”
Breast Tissue Biology Expands the Possibilities for Prevention of Age-Related Breast Cancers
Fresques, T., Zirbes, A., Shalabi, S., Samson, S., Preto, S., Stampfer, M. R., & LaBarge, M. A. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00174 · Cited by 7
Shi, Y., Wu, L., Ji, X., Li, Y., & Zhang, Z. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10372-2 · Cited by 7
“…risk factors of breast cancer include reproductive cycle, lifestyle, obesity, genetic susceptibility, DNA methylation, miRNA, and family history (Cheng et al. 2022; Jiralerspong et al. 2009; Joo et al. 2018; Li et al. 2010; Lin et al. 2022; Wang et al. 2022; Wen et al. 2022; Zhou et al. 2014).”
BackgroundMetformin as a Novel Component of Metronomic Chemotherapeutic Use: A Hypothesis
Duque, J. E., Vélez, J., Samudio, I. J., & Lai, E. (2012) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2012.04.002 · Cited by 7
Diabetes, diabetes therapies and cancer: what’s the link?
Seewoodhary, J., & Bain, S. C. (2011) · The British Journal of Diabetes · doi:10.1177/1474651411421024 · Cited by 7
Treatment of ErbB2 breast cancer by mitochondrial targeting
Eldad, S., Hertz, R., Vainer, G. W., Saada, A., & Bar‐Tana, J. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-00223-8 · Cited by 7
Tully, E., Bharti, S. K., Woo, J., Bhujwalla, Z. M., & Gabrielson, E. W. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1982599 · Cited by 7
Impact of type 2 diabetes on malignancies of the female reproductive system
Espinoza, C., Veas-Torres, J., Miranda, D. I., & Owen, G. I. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101459 · Cited by 6
Metformin in selected malignancies in women
Markowska, A., Stanisławiak‐Rudowicz, J., Kasprzak, T., Markowska, J., & Szarszewska, M. (2021) · Ginekologia Polska · doi:10.5603/gp.a2021.0222 · Cited by 6
“Moreover, metformin reduces the risk of cancer progression by 23% [11].”
BackgroundSynergistic Effect of Metformin and Lansoprazole Against Gastric Cancer through Growth Inhibition
Kao, H.-W., Tsai, K., & Lin, W. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.82407 · Cited by 6
“Many studies have demonstrated that metformin has anticancer effects in patients with ovarian, breast, prostate, and colorectal cancers [30, 31].”
BackgroundFröhlich, E., & Wahl, R. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01491.x · Cited by 6
“Metformin may also act in combination with chemostatic compounds: higher pathologic complete response rates were shown in breast cancer [92].”
BackgroundZhong, Z., Zhong, Z., Zhu, Z., Li, C., Zhang, C.-Y., Tong, M., & Jiang, H. (2015) · PubMed · Cited by 6
Alghalib, H. A. A., ALOTAIBI, A. D., Tulaihi, B. A., & AlGhaleb, S. A. A. (2020) · Clinical Diabetology · doi:10.5603/dk.2020.0062 · Cited by 6
“[5] reported that diabetic patients with breast cancer who received metformin had triple the pathological complete response rate in comparison with patients receiving neo-adjuvant chemotherapy alone (OR 2.”
ResultWhat every dentist should know about metformin, diabetes, and cancer.
Frykenberg, M. R. A., Schneider, A., & Bashirelahi, N. (2015) · PubMed · Cited by 6
Pollak, M. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0134 · Cited by 6
“Retrospective studies show that diabetic patients have a less-than-expected cancer incidence if they are on metformin (29, 30) and that diabetic breast cancer patients had superior rates of pathologic complete response to neoadjuvant chemotherapy if they took metformin (31), intriguing findings that require follow-up.”
BackgroundThe Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics
Goldvaser, H., Rizel, S., Hendler, D., Neiman, V., Shepshelovich, D., Shochat, T., Sulkes, A., Brenner, B., & Yerushalmi, R. (2016) · International Journal of Endocrinology · doi:10.1155/2016/4658469 · Cited by 6
Knowledge mapping of metformin use on cancers: a bibliometric analysis (2013–2023)
Pan, C., Wei, Y., Dai, J., Yang, L., Ding, Z., & Wang, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1388253 · Cited by 5
Sarajar, B. O., Rastegar‐Pouyani, N., Rasouli, A., Nikbakht, F., Majd, M., Ghahremani, M. H., Ostad, S. N., Jafarzadeh, E., & Dehghani, M. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102438 · Cited by 5
“Numerous studies have demonstrated a strong association be-tween pCR and the administration of the MET + PTX combination in breast cancer patients [32,36,38].”
Metformin and its derivatives in breast cancer: from glycaemic control to tumor-intrinsic pathways
Alim, R., & Akalanka, H. M. K. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02194-4 · Cited by 6
“For example, a retrospective analysis found that diabetic BC patients who received metformin during neoadjuvant chemotherapy had a significantly higher pCR rate compared to those not on metformin (24% vs. 8%, p = 0.007) [11].”
InfluentialAriaans, G., Tiersma, J. F., Evers, B., Gerding, A., Waaijer, S. J. H., Koster, R. A., Touw, D. J., Bakker, B. M., Reijngoud, D., de Jong, S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116362 · Cited by 5
“In epidemiological and retrospective studies, metformin use was associated with reduced breast cancer risk and improved response to neoadjuvant chemotherapy [13].”
BackgroundGennari, A., Sormani, M. P., Puntoni, M., Martini, V., Amaro, A. A., Bruzzi, P., & Pfeffer, U. (2020) · Breast Care · doi:10.1159/000509207 · Cited by 5
Dickler, M. N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.6393 · Cited by 5
“Recently, a retrospective cohort study suggested that patients with diabetes and breast cancer who were treated with metformin had a higher pathologic complete response rate with neoadjuvant chemotherapy than patients who were treated with other diabetes medications.(24) As a follow-up adjuvant trial to investigate th…”
ResultMetformin- A Promising Agent for Chemoprevention in BRCA1 Carriers
Kumar, N. B. (2012) · Hereditary Genetics · doi:10.4172/2161-1041.1000104 · Cited by 5
“007) [26], demonstrating the role of MET as an antineoplastic agent for breast cancer.”
BackgroundBrzački, V., Nagorni, A. V., Kallistratos, M. S., Manolis, A. J., & Lović, D. B. (2019) · Current Pharmacology Reports · doi:10.1007/s40495-019-00183-8 · Cited by 5
Saif, M. W., Rajagopal, S., Caplain, J., Goodman, M. D., Popowich, D. A., Orkin, B. A., Tsichlis, P. N., & Martell, R. E. (2021) · PubMed · Cited by 5
Breast Cancer Drug Repurposing a Tool for a Challenging Disease
Malik, J. A., Jan, R., Ahmed, S., & Anwar, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101378 · Cited by 5
Arafat, H. M., Omar, J., Shafii, N., Naser, I. A., Laham, N. A., Muhamad, R., Din, T. A. D. A. T., Shamallakh, O. M., & Shamallakh, K. M. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.2.717 · Cited by 5
“High glucose levels are crucial for the growth and development of BC cells (Jiralerspong et al., 2009; Zhao et al., 2020).”
BackgroundOsman, H. M. A., & Faggad, A. (2022) · Asian Pacific Journal of Cancer Biology · doi:10.31557/apjcb.2022.7.4.289-295 · Cited by 5
“Studies from Sweden and Korea showed that the glucose level was not associated with breast cancer risk [25] [33].”
BackgroundViollet, B., & Foretz, M. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70183-3 · Cited by 5
Goodwin, P. J. (2010) · Current Breast Cancer Reports · doi:10.1007/s12609-010-0024-2 · Cited by 5
“In the clinical setting, we have reported [43] that breast cancer survivors with insulin levels in the upper range of normal will experience a 22% reduction in fasting insulin levels and a 25% improvement in insulin resistance when given metformin for 6 months, providing evidence that metformin has clinically importan…”
BackgroundNew Potentiometric Sensor for Determination of Metformin
Кормош, Ж., Kormosh, N., Golub, S., Pachenko, Y., Yurchenko, O. M., Савчук, Т. І., Korolchuk, S., БОРКОВА, С., & Супрунович, С. В. (2022) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-022-02765-1 · Cited by 4
Computational Techniques for Drug Repurposing: A Paradigm Shift in Drug Discovery
Rao, M. R. P., Ghadge, I., Kulkarni, S. P., & Asthana, T. (2023) · Current Drug Therapy · doi:10.2174/1574885518666230207143523 · Cited by 6
Metformin: A Promising Radiosensitizer in Neoadjuvant Rectal Cancer Treatment
Georgopoulos, N. S., Tolia, M., Mauri, D., Kamposioras, K. V., Charalampakis, N., Tsoukalas, N., & Gkantaifi, A. (2023) · Reviews on Recent Clinical Trials · doi:10.2174/1574887118666230428114349 · Cited by 4
Hong, J. W. (2023) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2023.5.e9 · Cited by 4
Lee, J. H., & Kim, T. I. (2013) · Current Colorectal Cancer Reports · doi:10.1007/s11888-013-0198-x · Cited by 5
“[98] confirmed this adjuvant role of metformin in a neoadjuvant setting of a retrospective clinical study of breast cancer.”
BackgroundMetformin: Are Potential Benefits on Cancer Risk Extended to Cancer Survival?
Vecchia, C. L., & Bosetti, C. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0381 · Cited by 4
The Anticancer Effect of Metformin, the Most Commonly Used Anti-Diabetes Drug
Meng, S. (2014) · Cited by 4
Neamati, D., Khedri, A., Aberomand, M., Hemati, A. A., Mohammadzadeh, M., Baghbani, K. A., & Mohammadzadeh, G. (2021) · PubMed Central · doi:10.22038/ijbms.2021.58825.13069 · Cited by 4
“(30) in a clinical trial study showed that diabetic patients with breast cancer had a better pathological response if they took metformin simultaneously with chemotherapy than those who did not.”
BackgroundInfluence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma
Ono, M., Fujita, K., Kobayashi, K., & Masaki, T. (2023) · Hepatology Research · doi:10.1111/hepr.13912 · Cited by 4
Epidemiology of Cardio-Oncology
Lenneman, C. G., Kimmick, G. G., & Sawyer, D. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-43096-6_1 · Cited by 4
Preventive and (Neo)Adjuvant Therapeutic Effects of Metformin on Cancer
Jiao, Y., Wang, X., & Luo, Z. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91291 · Cited by 4
“[45] Metformin + chemotherapy The pCR rate in 68 diabetic patients treated with metformin, 87 diabetic patients without metformin,”
BackgroundResultBabak, M. V., Chong, K. R., Rapta, P., Ζαννίκου, Μ., Tang, H. M., Reichert, L., Chang, M. R., Kushnarev, V. A., Heffeter, P., Meier, S. M., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202102266 · Cited by 5
Insulin, Insulin Resistance, and Cancer Associations
Lipscombe, L. L. (2011) · Energy balance and cancer · doi:10.1007/978-1-4419-9911-5_5 · Cited by 4
“A more recent systematic review confirmed that metformin is associated with a significant reduction in cancer incidence [90], and one study found that metformin treatment among women with type 2 diabetes and breast cancer was associated with a significant improvement in complete pathologic response following adjuvant…”
BackgroundMecanismos antitumorales de la metformina: señalización, metabolismo, inmunidad y más allá.
Duque, J. E., López, C., Cruz, N., & Samudio, I. J. (2010) · Universitas Scientiarum · doi:10.11144/javeriana.sc15-2.amom · Cited by 6
“Still, the first evidence of the safety and efficacy of metformin as an adjuvant in the treatment of breast cancer was reported by the breast medical oncology group at MD Anderson Cancer Center in a retrospective study of 68 diabetic patients taking metformin, 87 diabetic patients not taking metformin, and 2,374 nondi…”
BackgroundMouna, B. M., Batra, A., Sharma, A., Kataria, B., Gogia, A., Sharma, J., Sharma, A., Mishra, A., Saikia, J., Deo, S., et al. (2025) · Cancer · doi:10.1002/cncr.70205 · Cited by 3
Calories and Cancer: The Role of Insulin-Like Growth Factor-1
Hursting, S. D., Smith, S. D., Harvey, A. E., & Lashinger, L. M. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0598-6_12 · Cited by 3
A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer
Lee, C., Lam, S. Y., Liu, A., Sison, C. P., & Zhu, X. (2023) · Clinical Medicine Insights Oncology · doi:10.1177/11795549231152073 · Cited by 4
Arioka, M., Miura, K., Han, R., Igawa, K., Takahashi‐Yanaga, F., & Sasaguri, T. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122807 · Cited by 3
Khouri, C., Dell’Aniello, S., Yin, H., Azoulay, L., & Suissa, S. (2025) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2025.111880 · Cited by 3
Bešič, N., & Šatej, N. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-416 · Cited by 3
“[3], our patients are older and have a lower mean BMI index.”
Hype versus Hope: Metformin and Vitamin D as Anticancer Agents
Lohmann, A. E., & Goodwin, P. J. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e69 · Cited by 2
Co-Managing Patients with Type 1 Diabetes and Cancer
Best, C. J., Thosani, S., Ortiz, M. R., Levesque, C. A., Varghese, S. S., & Lavis, V. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0766-y · Cited by 3
PPAC (programme personnalisé de l’après-cancer) : rationnel et mise en place
Gangler, A., Lesur, A., & Dalenc, F. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2595-7 · Cited by 3
“Elle pourrait également avoir un effet propre antitumoral par l’inhibition de mTOR [46].”
BackgroundDell’Atti, L., & Galosi, A. B. (2018) · International braz j urol · doi:10.1590/s1677-5538.ibju.2017.0046 · Cited by 3
“However, recent epidemiological studies have shown that metformin can reduce the risk of breast, pancreatic, colon and prostatic cancers and might even improve cancer prognosis (9-11).”
BackgroundPretta, A., Ziranu, P., Giampieri, R., Donisi, C., Cimbro, E., Spanu, D., Lai, E., Pecci, F., Balconi, F., Lupi, A., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.11.012 · Cited by 3
Arioka, M., Tetsuo, F., Inoue, T., Miura, K., Ishikane, S., Igawa, K., Tomooka, K., Takahashi‐Yanaga, F., & Sasaguri, T. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122278 · Cited by 3
Antidiabetikus kezelés, mint újabb lehetőség a daganatok komplex terápiájában
Bánhegyi, R. J., Rus-Gal, P. O., Nagy, Á. K., Martyin, T., Wagner, R. J., Varga, R., & Pikó, B. (2010) · Magyar Onkológia · doi:10.1556/monkol.54.2010.4.5 · Cited by 3
Keri, R. A., Distelhorst, C., Sharifi, N., & Berger, N. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00031-6 · Cited by 3
Metabolic Pathways of Eukaryotes and Connection to Cell Mechanics
Mierke, C. T. (2020) · Biological and medical physics, biomedical engineering · doi:10.1007/978-3-030-58532-7_17 · Cited by 2
Targeting translation initiation in breast cancer
Akçakanat, A., Hong, D. S., & Meric‐Bernstam, F. (2014) · Translation · doi:10.4161/trla.28968 · Cited by 3
“For instance, patients with breast cancer and diabetes on metformin and neoadjuvant chemotherapy have a higher pathologic complete response rate than either breast cancer patients with diabetes receiving neoadjuvant chemotherapy but not metformin or nondiabetic breast cancer patients.(162) The insulin-independent mode…”
BackgroundSelf-citationMcLean, R. C., & Logue, J. (2014) · Current Nutrition Reports · doi:10.1007/s13668-014-0105-3 · Cited by 3
Doses, mechanisms and the dandelion and hormetic phenomena
Martı́n-Castillo, B., Vázquez‐Martín, A., Oliveras‐Ferraros, C., & Menéndez, J. A. (2010) · Cited by 3
Toi, M., Ohashi, Y., Seow, A., Moriya, T., Tse, G. M.-K., Sasano, H., Park, B., Chow, L. W. C., Laudico, A. V., Yip, C. H., et al. (2010) · Cited by 3
Long non‐coding RNAE330013P06 promotes progression of breast cancer with type 2 diabetes
Chen, R., Shi, P., Zhang, Y., Wu, H., Li, X., Yang, W., Luo, F., JinmingXue, Yao, L., Yang, J., et al. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23172 · Cited by 3
Tharakan, S., Zimmerman, B. S., Ru, M., Blanter, J., Cascetta, K. P., & Tiersten, A. (2020) · Oncology · doi:10.1159/000506076 · Cited by 3
Mechanisms Linking Obesity to Cancer Risk
Imayama, I., Mason, C. E., & Duggan, C. R. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7551-5_6 · Cited by 3
Metformin Therapy and Breast Cancer Incidence in the Ha’il Region
Osman, M. E., Muqbel, T., Abduallh, A., Alanazi, S., Khalifa, N. E., Khojali, W. M. A., Elagib, H. M., Hussein, W., & Abdallah, M. H. (2023) · Healthcare · doi:10.3390/healthcare11030321 · Cited by 3
“In a study focused on determining whether metformin use can be linked to a change in the pathologic complete response (PCR) rates in diabetic patients with breast cancer after neoadjuvant chemotherapy, it was discovered that the diabetic patients using metformin showed a greater PCR rate than diabetics who did not tak…”
BackgroundEpithelial to Mesenchymal Transition (EMT)
Malviya, R., Singh, A. K., & Yadav, D. (2023) · doi:10.1002/9781394209866.ch7 · Cited by 3
Metadata
- Authors
- Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- From the Departments of Breast Medical Oncology, Biochemistry and Molecular Biology, Quantitative Sciences, Surgical Oncology, Pharmacy, Molecular and Cellular Oncology, and Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and the Department of Gynecology and Obstetrics, University of Muenster, Muenster, Germany.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-07-10
- Volume
- 27
- Issue
- 20
- Pages
- 3297-3302
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC2736070
- OpenAlex
- W2171998898
- Cited by
- 880
- References
- 42
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 18 · 2023: 34 · 2022: 31 · 2021: 51 · 2020: 43 · 2019: 60 · 2018: 34 · 2017: 42 · 2016: 54 · 2015: 53 · 2014: 73 · 2013: 97 · 2012: 76
- FWCI
- 35.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Breast Cancer Research Foundation
- Amgen
- American Society of Clinical Oncology
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5k23ca121994-03)
- National Cancer Institute (1K23CA121994-01), K23-CA121994, 1K23CA121994)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Keywords
- metformin, breast cancer, diabetes mellitus, neoadjuvant chemotherapy, pathological complete response, predictors of treatment response
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Diabetes Mellitus, Female, Humans, Hypoglycemic Agents, Metformin, Middle Aged, Remission Induction, Multivariate Analysis, Logistic Models, Survival Analysis, Treatment Outcome, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
